Read twice and referred to the Committee on Finance.
Creates a Medicare ‘breakthrough device’ pathway: the FDA-designated device gets a 4-year transitional coverage period during which Medicare generally covers it unless used off-label or shown to present undue risk. Establishes a statutory process for manufacturers to apply for a breakthrough designation (tied to FDA priority review under 515B), requires the HHS Secretary to decide designation applications within 6 months, and requires CMS to issue an applicable national coverage determination before the end of the transitional period if requested timely.
Liberals emphasize patient access and innovation; conservatives stress safety and spending.
Relative to its intended legislative type, this bill is a substantive statutory amendment to Medicare coverage rules that is comparatively well-structured: it provides clear definitions, ties designation to existing FDA statutory mechanisms, sets timelines for agency action, specifies reporting requirements, and supplies a targeted appropriation for implementation.
Creates a Medicare ‘breakthrough device’ pathway: the FDA-designated device gets a 4-year transitional coverage period during which Medicare generally covers it unless used off-label or shown to present undue risk.
Establishes a statutory process for manufacturers to apply for a breakthrough designation (tied to FDA priority review under 515B), requires the HHS Secretary to decide designation applications within 6 months, and requires CMS to issue an applicable national coverage determination before the end of the transitional period if requested timely.
Requires annual reports to Congress on applications and designations, delays the start of the designation program until 18 months after enactment, and appropriates $10 million per year for CMS for fiscal years 2026–2031 to implement the changes.
Focused, administrable change with modest appropriations improves access and aligns with FDA processes, but unknown Medicare cost effects and safety scrutiny lower likelihood.
Relative to its intended legislative type, this bill is a substantive statutory amendment to Medicare coverage rules that is comparatively well-structured: it provides clear definitions, ties designation to existing FDA statutory mechanisms, sets timelines for agency action, specifies reporting requirements, and supplies a targeted appropriation for implementation.
Liberals emphasize patient access and innovation; conservatives stress safety and spending.
These are examples from the analysis, not a ranked list of the most-affected groups.
Liberals emphasize patient access and innovation; conservatives stress safety and spending.
Generally supportive because it speeds Medicare patient access to potentially life‑saving medical devices and provides a clear pathway for coverage.
Will want stronger post‑market safeguards, equity protections, and mechanisms to prevent industry abuse of the designation.
Cautious support: the bill addresses a real problem—coverage delays for novel devices—while adding procedural timelines and modest funding.
Wants clearer evidence standards, cost controls, and measurable accountability.
Mixed to somewhat opposed: likes faster patient access and innovation incentives, but worries about added federal mandates, new spending, and coverage of devices with limited evidence.
May prefer market adoption without extended federal coverage guarantees.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Focused, administrable change with modest appropriations improves access and aligns with FDA processes, but unknown Medicare cost effects and safety scrutiny lower likelihood.
The bill has not accumulated any surfaced votes yet.
Liberals emphasize patient access and innovation; conservatives stress safety and spending.
Focused, administrable change with modest appropriations improves access and aligns with FDA processes, but unknown Medicare cost effects a…
Relative to its intended legislative type, this bill is a substantive statutory amendment to Medicare coverage rules that is comparatively well-structured: it provides clear definitions, ties designation to existing FDA…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.